BOO!!
GAITHERSBURG, Md., Dec 2 (Reuters) - Procter & Gamble Co.'s
PG testosterone patch needs to undergo more study to
identify potential, long-term safety risks before it could be
approved, a U.S. advisory panel ruled on Thursday.
The Food and Drug Administration will consider the panel's
advice before deciding whether to approve the patch called
Intrinsa, which is being developed with Watson Pharmaceuticals
Inc. WPI. The FDA usually follows the recommendations of
its advisory panels.
GAITHERSBURG, Md., Dec 2 (Reuters) - Procter & Gamble Co.'s
PG testosterone patch needs to undergo more study to
identify potential, long-term safety risks before it could be
approved, a U.S. advisory panel ruled on Thursday.
The Food and Drug Administration will consider the panel's
advice before deciding whether to approve the patch called
Intrinsa, which is being developed with Watson Pharmaceuticals
Inc. WPI. The FDA usually follows the recommendations of
its advisory panels.
